Navigation Links
Patients with treatment-resistant CLL respond positively to stem cell transplants

(WASHINGTON, July 1, 2010) Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology. About 15,000 new CLL cases were diagnosed in the United States in 2009 and about 4,000 deaths were documented (according to the American Cancer Society). While survival rates for leukemia have generally improved in the last decade, patients with rare, more aggressive forms of CLL do not respond well to standard chemotherapy-based and targeted treatments and often die within a few years of diagnosis.

Patients with CLL who are treatment-resistant (do not respond to chemotherapy and targeted antibody combination regimens) have been shown to have genetic abnormalities that predict their lack of response. In this study, researchers investigated whether alloSCT could be an effective treatment for this patient population, independent of underlying genetic abnormalities.

"This study, which is one of the largest of its kind, confirms that allogeneic stem cell transplants are a promising therapeutic option for treatment-resistant CLL patients fighting particularly aggressive disease, regardless of their genetic risk profile," said Peter Dreger, MD, of the Department of Medicine, University of Heidelberg, Germany, and lead author of the study. "However, because stem cell transplants come with serious risks, they should be reserved for only this group of patients until further studies can be done."

In alloSCT, blood stem cells are collected from a donor and then infused into the patient where they travel to the bone marrow and begin to produce new blood cells, replacing those that have been affected as a result of the disease. This type of treatment can pose serious complications, some of which are potentially fatal. In this prospective phase II study, a total of 90 patients with treatment-resistant CLL received alloSCT, and stem cell donors were either healthy siblings or unrelated, but matched, volunteers.

Prior to the transplant, patients in this study received conditioning, a standard therapy administered immediately before a stem cell transplant to help prepare the body to receive and accept the transplanted cells. The research team used a reduced-intensity conditioning approach with two common chemotherapies (fludarabine and cyclophosphamide) to reduce complications and allow the donor stem cells to fight the disease themselves.

After treatment with alloSCT, more than 40 percent of participants with this otherwise fatal disease enjoyed long-term freedom from relapse. These findings suggest that alloSCT is a feasible and potentially curative treatment for patients with high-risk CLL and should be considered for this patient population.


Contact: Wendy Stokes
American Society of Hematology

Related medicine news :

1. Study shows short-term kidney failure in heart patients may not be as detrimental
2. Predicting Alzheimers Risk in Patients With Cognitive Problems
3. Beating doctor burnout and protecting patients
4. Fewer than half of breast cancer patients adhere to hormonal therapy regimen, study finds
5. Tray bleaching may improve oral health of elderly, special-needs patients
6. Brain Stimulation Seems to Boost Language Skills in Alzheimers Patients
7. Novel radiotracer shines new light on the brains of Alzheimers disease patients
8. Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression
9. Cardiac MRI in the ER cuts costs, hospital admissions for chest pain patients
10. Pre-emptive pain regimen decreased opioid usage in patients undergoing robotic prostatectomy
11. What affects the gastrointestinal symptoms in peritoneal dialysis patients?
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Physicians’ Education Resource®, LLC ... today announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will be ... and treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with powerful ...
(Date:12/1/2015)... ... 2015 , ... Growth in medical payments per workers’ compensation claim in Louisiana ... and nonhospital care, according to a recent study by the Workers Compensation Research Institute ... found medical payments per claim with more than seven days of lost time continued ...
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. ... results enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... solutions for the care management and population health arenas, is pleased to announce ... and cost containment services, has successfully implemented the ACUITY Complete Care™ Management to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Germany , December 1, 2015 /PRNewswire/ ... leading global manufacturer of eye and gaze tracking solutions, ... SMI remote eye trackers as a component of its ... concussions, eye sight, and medical and performance issues in ... part of SMI,s mass-market-ready eye tracking platform, which is ...
(Date:12/1/2015)... 1, 2015 --> ... van Leeuwenhoek Hospital (NKI-AVL), among the world,s largest ... Leksell Gamma Knife® Icon™, the company,s latest generation ... --> --> With the ... treatments, Leksell Gamma Knife Icon offers greatly enhanced ...
(Date:12/1/2015)... Dec. 01, 2015 ... "Drug Delivery Technology Market 2015 - Forecast ... --> ) has announced the addition ... - Forecast to 2020" report to their ... ) has announced the addition of the ...
Breaking Medicine Technology: